Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2020 Mar;53(3):e12770.
doi: 10.1111/cpr.12770. Epub 2020 Feb 5.

The role of the cancer testis antigen PRAME in tumorigenesis and immunotherapy in human cancer

Affiliations
Review

The role of the cancer testis antigen PRAME in tumorigenesis and immunotherapy in human cancer

Yichi Xu et al. Cell Prolif. 2020 Mar.

Abstract

Preferentially expressed antigen in melanoma (PRAME), which belongs to the cancer/testis antigen (CTA) gene family, plays a pivotal role in multiple cellular processes and immunotherapy response in human cancers. PRAME is highly expressed in different types of cancers and is involved in cell proliferation, apoptosis, differentiation and metastasis as well as the outcomes of patients with cancer. In this review article, we discuss the potential roles and physiological functions of PRAME in various types of cancers. Moreover, this review highlights immunotherapeutic strategies that target PRAME in human malignancies. Therefore, the modulation of PRAME might be useful for the treatment of patients with cancer.

Keywords: PRAME; immunotherapy; oncogene; proliferation; tumorigenesis.

PubMed Disclaimer

Conflict of interest statement

The authors declare that they have no conflict of interest.

Figures

Figure 1
Figure 1
PRAME is regulated by upstream molecules and exerts its biological functions via the regulation of downstream targets in cancer. SOX17, MZF1, miR‐211 and miR‐421 regulate the expression of PRAME. PRAME exerts its biological functions via targeting p21, p53, RAR, TRAIL, S100A4 and HSP27, leading to the control of several cellular processes, including cell proliferation, apoptosis, differentiation, growth arrest and chemotherapy sensitivity

Similar articles

Cited by

References

    1. Ikeda H, Lethé B, Lehmann F, et al. Characterization of an antigen that is recognized on a melanoma showing partial HLA loss by CTL expressing an NK inhibitory receptor. Immunity. 1997;6(2):199‐208. - PubMed
    1. Wadelin F, Fulton J, McEwan PA, Spriggs KA, Emsley J, Heery DM. Leucine‐rich repeat protein PRAME: expression, potential functions and clinical implications for leukaemia. Mol Cancer. 2010;9:226. - PMC - PubMed
    1. Goodison S, Urquidi V. The cancer testis antigen PRAME as a biomarker for solid tumor cancer management. Biomark Med. 2012;6(5):629‐632. - PubMed
    1. Ortmann CA, Eisele L, Nückel H, et al. Aberrant hypomethylation of the cancer‐testis antigen PRAME correlates with PRAME expression in acute myeloid leukemia. Ann Hematol. 2008;87(10):809‐818. - PubMed
    1. Roman‐Gomez J, Jimenez‐Velasco A, Agirre X, et al. Epigenetic regulation of PRAME gene in chronic myeloid leukemia. Leuk Res. 2007;31(11):1521‐1528. - PubMed